Biotech Briefing: Trefoil Raises $28 Million for FGF-1 Treatment to Reverse Vision Loss

vision loss treatment Biotech BriefingReports + Research Trefoil Raises $28 Million for FGF-1 Treatment to Reverse Vision Loss For patients with corneal dystrophies, a cornea transplant surgery is currently the only option to prevent blindness. Trefoil Therapeutics is hoping to change that with TTHX1114, an engineered form of fibroblast growth factor 1 (FGF-1).? The goal of the treatment is …

The post Biotech Briefing: Trefoil Raises $28 Million for FGF-1 Treatment to Reverse Vision Loss appeared first on Hatch.